Affiliation:
1. Health Science Institute, International Integration University of Afro-Brazilian Lusophony (UNILAB), Redenção - CE, Brazil
2. Oswaldo Cruz Foundation (FIOCRUZ CEARÁ), Eusébio - CE, Brazil;
3. Oswaldo Cruz Foundation (FIOCRUZ CEARÁ), Eusébio - CE, Brazil
4. Post-graduate Program in Pharmaceutical Sciences (PPGCF), Federal University of Ceará (UFC), Fortaleza-CE, Brazil
5. Northeast Biotechnology Network (RENORBIO), State University of Ceará (UECE), Fortaleza-CE, Brazil
Abstract
Background:
Neglected parasitic diseases constitute a broad spectrum of clinical
conditions that, in the chronic phase, lack effective therapies for the target population.
The utilization of vaccines based on liposomal nanocarrier systems is emerging,
thereby enhancing clinical outcomes in various comorbidities. Consequently, this study
aims to assess the immunological activity induced by liposomal nanocarriers against neglected
parasitic diseases.
Methods:
For the review, the Pubmed, Embase, and Lilacs databases were used using
the descriptors vaccine, parasite, and liposome. The following inclusion criteria were
adopted: in vivo and in vitro experimental articles. As exclusion criteria: book chapters,
editorials, literature reviews and duplicate articles found during the database search.
Results:
A total of 226 articles were identified, from which 34 were selected for review.
The primary diseases identified included Babesia bovis, Entamoeba histolytica, Leishmania
braziliensis, Leishmania donovani, Leishmania major, Leishmania infantum, Plasmodium
falciparum, Plasmodium chabaudi, Plasmodium chabaudi, Plasmodium yoelii,
Toxoplasma gondii and Trypanosoma cruzi. An elevation in cytokines such as GM-CSF,
MCP-1, INF-γ, TNF-α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-17 was observed in
the studies evaluated regarding the parasitic diseases. Furthermore, cytokines such as
IL-4, IL-10, and TGF-β were diminished with the administration of the vaccine systems
in those studies.
Conclusion:
Therefore, the administration of liposomal nanovaccine systems can effectively
ameliorate the clinical condition of patients by modulating their immunological
profile.
Publisher
Bentham Science Publishers Ltd.